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ABSTRACT 
Aim:Tb compare the efficacy of electroconvulsive therapy (ECT) with risperidone in 
the treatment of lorazepam non-responsive catatonia. Materials and methods: Inpatients 
with non-affective catatonia (n= 18) non-responsive to at least five-day trial of lorazepam 
(6-8 mg/day) were randomised into two groups in a double blind randomised design. 
Written informed consent was obtained. Four were dropped from the trial as they 
were found to have depressive catatonia. One group received true ECT (thrice weekly, 
n=8) plus oral placebo while the other received sham ECT plus risperidone (4-6 mg/ 
day). Bush-Francis Catatonia Rating Scale (BFCRS) was administered twice weekly to 
assess improvement in catatonic symptoms over a period of three weeks. The two 
groups were compared using two-way RMANOVA. Results: BFCRS scores reduced 
markedly over treatment course and this reduction was more profound in the ECT 
group (p=0.035). Shorter the duration of illness greater was the response (lower 
scores of BFCRS). Conclusions: Superior clinical efficacy of ECT over neuroleptics in 
catatonia is confirmed by this randomized clinical trial. 
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INTRODUCTION 
.Catatonia is a syndrome of motor ab-
normalities in association with disorder of 
mood, behaviour or thought (Mahendra, 
1981). Catatonia is both a symptom and 
diagnosis by itself. It is a medical emergency. 
A detailed review of organic conditions 
producing catatonia is described elsewhere 
(Ahuja, 2000). Functional illnesses, which 
produce catatonia, include mood disorder 
(mania and depression), schizophrenia and/ 
<>r dissociation. Rarely it can be a manifes-
tation of other psychiatric illness such as 
obsessive-compulsive disorder (Jagadccshan 
et al, 2002). Benzodiazepine, particularly 
lorazepam, is the treatment of choice in 
functional catatonia (Greenfield ct al, 1987; 
Bush et al, 1996a; Payee et al, 1999). Nearly 
"0-80% of the patients improve within 48-
72 hours of lorazepam trial (6-8mg/day). 
Electroconvulsive therapy (ECT) is an al-
ternative form of treatment in catatonia. 
ECT is found to be useful in lorazepam 
non-responsive catatonic patients (Rohland 
et al, 1993; Bush et al, 1996a). Catatonic 
symptom in severe depression also had a 
good prediction to ECT response (Abrams, 
1997; Joseph, 1999). Many psychiatrists 
consider catatonia as a subtype of schizo-
phrenia and have therefore used neuroleptic 
drugs with success (Joseph, 1999). Other 
agents used in the treatment include 
amobarbital, lithium and carbamazepinc 
(Abrams and Taylor, 1976; Abrams, 1997). 
However their use is limited in clinical 
practice. There arc also no comparative 
trials with these agents in the treatment of 
catatonia. This study compared the efficacy 
of FX7T over antipsychotic drug - risperidone 
MATERIALS AND METHODS 
Subjects 
Drug naive inpatients (n=68) with a 
diagnosis of non-atfective functional cata-
tonia were considered for the trial. The 
clinical diagnosis (1CD-10; WHO, 1992) was 
made based on the detailed history obtained 
from patient's relatives and previous records. 
All patients received a trial of lorazepam (6-
8mg/day PO or i.v. for a maximum period 
of 5-days). Fifty patients (73.5%) responded 
to treatment. Those not responding (having 
at least two catatonic signs; n=18) were 
considered for the study. None of the 
patients had any history suggestive of 
underlying organicity. None had received 
ECT in the past. Basic investigations (com-
plete hacmogram, biochemistry, serum elec-
trolytes and urine examinations) were nor-
mal. The clinical diagnosis in lorazepam 
non-responsive patients was confirmed in-
dependently by another psychiatrist (CiK) 
during the study period by clinical interview. 
Nine received a diagnosis of schizophrenia, 
five had psychosis NOS while the rest four 
had depressive catatonia. Depressive cata-
tonic patients were excluded from analysis. 
Thus the final sample consisted of 14 
patients (3 females). The mean±SD age of 
the sample was 23.8±4.1 years (range 20-
47 years). They were randomised into one 
of the two groups (OK). One group re-
ceived true ECT plus placebo (ECT group; 
n=8) while the other received sham ECT 
plus risperidone (risperidone group; n=6). 
lorazepam was stopped in all patients 
before entering the study. The study was for 
a period of three weeks. 
Consent for the study was obtained from 
the spouse or a nearest family member and 
also from the patient during the study 
period when he was able to provide con-
sent. The psychiatry department at National 
Institute of Mental Health and 
Neruosciences, Bangalore approved the study 
protocol. 
Treatment 
Patients in ECT group received bilateral 
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modified K( T prescribed thrice weekly until 
clinical improvement was maximum and 
maintained for at least one week. Threshold 
was assessed at first KCT session using 
titration method and in subsequent sessions 
marginally suprathrcshold doses (60mC + 
threshold) administered. Thiopentone (4mg/ 
kg body weight), succinylcholine (lmg/kg 
body weight) and atropine (0.6mg) were 
used for modification, Cult method was 
used to record motor seizure duration and 
computerized I'.l'.Ci was used for recording 
cerebral seizure at all KCT sessions. These 
patients also received oral placebo given in 
BIO doses. No psychotropic medications 
were administered during the study period 
except in one for agitation (lorazepam 2mg 
at night). After the completion of the study 
period patients were starred on risperidone 
(4-omg/day). 
Patients in risperidone group received 
oral risperidone in BID doses, 2mg per day 
(day-1) and that was increased to 4 to 6mg 
over two to tour days until patient devel-
oped subtle extrapyramidal symptoms (ITS). 
Sham KCT was administered at thrice weekly 
KCT using intravenous thiopentone (4mg/ 
kg bodv weight). The Bl' cuff was tied in 
the right leg and the KEG electrodes were 
applied over the scalp in sham KCT patients 
too. 
Rating scales 
In lorazepam non-responsive patients 
(n - IS), the clinical diagnosis was confirmed 
by clmic.il interview (ICD-10; WHO, 1992) 
by another psychiatrist (CiK) at baseline and 
during the studs' period. 
Patients were evaluated for catatonic 
signs severity using BushTrancis Catatonia 
Rating Scale (BI'CRS; Bush et al, 1996b) 
adminMcrcd before KCT (baseline) and 
twice weekly thereafter. Another psychiatrist 
tllK': administered BI'CRS on the fifth day 
of lorazepam treatment. Patients who had 
no or only one catatonic sign on BI'CRS 
were termed 'respoiulers'. Those who had 
more than one were termed 'non-respon-
sive' and continued in the trial. 
Psvchopathologv was assessed once every 
week using Positive and Negative Syndrome 
Scale (J'ANSS; Kay et al. P>8~). PANSS svas 
not administered at baseline (as formal 
interviesv was not possible). Scores were 
available in only eight patients at the end 
of one week and for all patients at the end 
of second and third sveek. 
Columbia side-effect checklist (Sackeim 
et al, 1987) for KCT-induced side effects 
and Simpson-Angus rating scale (Lejos'cux 
et al, 1993) for risperidonc-induced 
extrapyramidal side effects were adminis-
tered once every week in all patients. A 
single psychiatrist ((INS) administered all 
the above rating scales through out the 
study period. He svas blind to randomisation. 
Statistics 
Fisher's test svas used to compare the 
demographic and clinical characteristics of 
the patients between the KCT group and 
risperidone group. The diagnostic agree-
ment between the two raters in 18 patients 
svas assessed by Kappa. The interrater 
reliability on baseline BI'CRS score was 
measured by intraclass correlation. Tsvo-svay 
RMANOVA was used to compare the 
BI'CRS scores between the ECT group and 
risperidone group over thrce-sveek period. 
Similarly PANSS scores as-ailable at the end 
of second and third week svere compared 
between the two groups using two-way 
RMANOVA. 
TABLE I: Sociodemographic and clinical 
risperidone group (mean±SD) 
RESULTS 
All subjects (n=14) completed the 3-
wcek study period. The demography and 
clinical data of the KCT and risperidone 
groups arc given in Table-1. The two groups 
svere comparable. The clinical diagnosis had 
high interrater reliability (Kappa=0.75). The 
mean baseline BFCRS scores svere similar 
between the two groups (Fig-1). The 
intraclass correlation coefficient svas 0.76. 
Both groups demonstrated an improve-
ment in BI'CRS by the end of third sveek. 
The improvement svas greater in KCT 
group compared to risperidone group at any 
treatment week and svas statistically signifi-
cant (p=().()35, l'ig-2). In KCT group, KCT 
was required to be continued beyond the 
threc-sveek study period in four patients. In 
three patients of the risperidone group, 
ECT was advised after the study period. 
PANSS scores improved both in the 
KCT group and the risperidone group by 
the end of third week. The impros-ement 
in positis'c psychopathology scores svas 
significantly greater in ECT group com-
pared to risperidone group (p=0.04). 
There svere no major untosvard side 
effects cither with ECT or risperidone. 
variables between ECT group and 
Variables 
Age (years) 
Sex (male:female)* 
Diagnosis (schiiophrenia:psychosis NOS)* 
Duration of illness (months) 
Range (months) 
Duration of catatonic signs (weeks) 
Range (weeks) 
Baseline BFCRS scores 
Range 
frequency. 
The two groups were comparable in all 
ECT Group 
(n=8) 
24.714.7 
1:7 
5:3 
33.0+41.9 
0.25-120 
I4.9±20.7 
1-48 
13.613.3 
8-17 
Risperidone 
Group (n=6) 
22.513.4 
2:4 
4:2 
50.3140.6 
6-108 
69.8! II 3.79 
2-288 
13.012.0 
10-15 
variables measured. 
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There was higher incidence of headache 
(n=6) and transient memory impairment 
(n=4) in F.CT group. There was no major 
on-the-table complication with ECT except 
one having prolonged seizures at two ECT 
sessions (aborted using 5mg intravenous 
diazepam). Two patients in risperidone group 
I had tremors and mild rigidity and received 
trihexyphenydyl (2-4mg/day) along with 
risperidone. One had akathisia but no 
additional intervention was needed clinically. 
None had dystonia or neuroleptic malignant 
syndrome. 
DISCUSSSION 
The results of this study demonstrated 
that ECT was more efficacious than 
risperidone in the treatment of non-affective 
catatonia non-responsive to lorazepam. 
BFCRS and PANSS scores improved more 
with F.CT than risperidone and were sta-
tistically significant. To our knowledge this 
is the only double blind randomised study 
that has compared two different treatments 
in catatonia. Hence no comparison is pos-
sible. The study consisted of a homogenous 
group of non-affective catatonic patients 
from a representative inpatient sample. There 
was high interrater reliability in clinical 
diagnosis and baseline BFCRS scores. 
Most of the catatonic patients (73.5%) 
improved with lorazepam and within 48-72 
hours. This response was in comparison to 
earlier studies (Greenfield et al, 1987; 
Ungavari et al, 1994; Bush et al, 1996; Payee 
et al, 1999). On comparison with the non-
responders (n=18), the earlier group had 
relatively short duration of catatonia (12.5 
weeks v/s 38.4 weeks) and were largely 
males (38 v/s 3). 
Unlike lorazepam, which is useful in 
ameliorating the catatonic signs, ECT also 
produced marked improvement in underly-
ing psychiatric illness. The PANSS scores 
improved better with ECT compared to 
risperidone. Positive symptoms improved 
more than negative symptoms. 
Univariate analysis was attempted to 
examine predictors of response in catatonia. 
Patients treated with ECT and shorter 
duration of catatonia had lower BFCRS 
scores at the end of three-week. There was 
no association between the number of 
catatonic signs and outcome. These findings 
support earlier observations (Rosebush et al, 
1992; Bush et al, 1996). 
Response to ECT was dramatic in cata-
tonia in previous studies (Rosebush et al, 
1992; Bush et al, 1996). The average number 
of ECT ranged from 2-4 and clinical 
improvement was marked. In our study 
though patients improved with F.CT. the 
average number of ECT was 8.87 (range 
6-13) in ECT group. We deliberately selected 
non-affective catatonia. Nearly 65% of the 
patients in previous studies had affective 
illness (Bush et al, 1996). Secondly the 
duration of catatonia prior to entry in their 
study was less than a week while it was 38.4 
weeks in our study. 
Catatonia scores reduced significantly in 
the F.CT group. However four out of eight 
patients continued to receive ECT beyond 
a three-week period (10-13 ECT) though 
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the catatonic signs had improved. ECT was 
continued in th':sc patients for their psy-
chotic symptoms. Three patients from 
risperidone group received ECT along with 
risperidone (6mg/day) after the study pe-
riod as the catatonic signs persisted. Two 
of them completely remitted while the third 
persisted to have near mutism and 
negativism. These observations suggest that 
ECT treatment may be initiated early in 
catatonic patients, when indicated, to pro-
duce maximum benefits. Some advocate the 
use of ECT to augment antipsychotic re-
sponse in catatonic schizophrenia (Ameri-
can Psychaitric Association, 1997). However 
it needs to be explored whether ECT plus 
antipsychotic drug in catatonia has an ad-
vantage over ECT alone. 
In this studv, four patients were excluded 
as they had depressive catatonia. It is likely 
that when patient is brought in catatonic 
state, the primary diagnosis is difficult to 
establish. However, once underlying 
organicity is ruled out and patient is non-
responsive to lorazepam treatment, ECT 
can be administered safely instead of giving 
a prolonged trial of psychotropic drugs 
(such as risperidone). In our study too 
except one who had prolonged seizure, 
none of the ECT patients had complica-
tions. However, EEG and ECG monitoring 
during ECT may be preferred in catatonics. 
Some have argued that addition of 
neuroleptics in catatonic patients may pre-
cipitate catatonic signs (Gercnbcrg, 1977; 
Taylor, 1990). There is also risk of NMS 
(Mann ct al, 1986; Philbrick and Rumnans, 
1994) which is life threatening. However, 
none in our sample had any such serious 
effects. However, one has to be cautious 
and watch for such symptoms and gradually 
increase neuroleptics if preferred over ECT. 
Although ECT is better than neuroleptic 
drugs in the treatment of catatonia as 
suggested bv our study too, one needs to 
be cautious in use. Fifty percent of the 
patients in both the ECT group and 
risperidone group needed ECT beyond the 
three-week study period. ECT patients did 
not obtain total recovery. This may indicate 
that the extent of improvement with ECT 
in catatonia mav not be as dramatic as 
generally believed. 
There are technical difficulties in con-
ducting trials of this kind. Although ECT 
is better in catatonic patients the inherent 
difficulties include: a) most of the patients 
with catatonia improve with benzodiazepines, 
b) it is difficult to classify catatonic patients 
into affective and non-affective illness on 
presentation, c) if non-affective catatonia, 
whether risperidone is the choice in treat-
ment or continuing benzodiazepine im-
proves the clinical condition? Under these 
considerations the results of this study is 
to be weighed with caution. Further, the 
limitations of the study. These include 
relatively small sample size and the study 
restricted to three-week period. Antipsyhotic 
effects arc maximum after three to four 
weeks of treatment. Also the dose of 
risperidone was gradually increased over 
first few days. This might have resulted in 
lower response in both the catatonic signs 
and psychopathology scores in the 
risperidone group. 
Summarising the literature existing, 
benzodiazepam should be chosen as the 
treatment of choice in catatonia. In those 
not responding, one should not wait for the 
prolonged drug trials continuing clinical 
deterioration. Many have supported the 
usage of ECT in lorazepam non-responsive 
catatonia. Fricchione (1989) recommend, 
"given the significant morbidity and mortal-
ity associated with catatonia, ECT should 
be considered if an expeditious 48-72 hours 
benzodiazepine trial is unsuccessful". This 
double blind design favours the usage and 
safety of ECT over risperidone. 
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